Thursday, October 8, 2026

Treasury Yields Surge to 4.32-4.34%, Crushing High-PEG Tech Valuations

The 10-Year Treasury yield has climbed from 3.97% to 4.32-4.34%, triggering valuation compression across high-growth technology stocks. Lightspeed Commerce fell 5.58% and Autodesk dropped 3.45% on May 12 while the broader market rose. Stocks with elevated PEG ratios face the sharpest repricing as rate expectations reset.

LM Salvado
LM Salvado

May 13, 2026

Treasury Yields Surge to 4.32-4.34%, Crushing High-PEG Tech Valuations
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The 10-Year Treasury yield has risen from 3.97% to 4.32-4.34%1, forcing a broad repricing of growth equity valuations. The move is not marginal — it shifts the discount rate applied to future earnings across every sector.

High-PEG stocks bear the heaviest burden. When yields rise, the present value of distant cash flows falls sharply. Companies priced on earnings years out suffer the most. This is not theory — it showed up directly in May 12 trading.

Lightspeed Commerce (LSPD) dropped 5.58%1 on a day the broader market gained. Autodesk fell 3.45%1 in the same session. CI&T has underperformed the S&P 500 year-to-date1. None of these declines followed negative company-specific news — the pressure came from the rate environment.

The PEG ratio (price-to-earnings divided by growth rate) measures how much investors pay per unit of future growth. DKS carries a PEG of 3.21 and Booz Allen Hamilton (BAH) sits at 4.451 — both well above industry norms. At 3.97% yields, those multiples were defensible. At 4.34%, the math changes.

The 10-Year Constant Maturity Rate moved from 4.29 to 4.34%1, confirming the yield pressure is broad and sustained, not a single-day spike. Markets are recalibrating the risk-free rate assumption embedded in every discounted cash flow model.

The pattern divides markets cleanly. Value stocks with near-term earnings and low PEG ratios are relatively insulated. Growth stocks — especially in software and AI infrastructure — see their valuation cushion erode with each basis point move higher.

Investors holding high-PEG positions face a structural headwind until yields stabilize or reverse. A threshold around 4.3% appears to accelerate the divergence between rate-sensitive growth names and the broader index. That threshold has now been crossed.

Portfolio construction that ignores duration risk in equity positions — not just bond positions — is the central mistake of this rate environment.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com